Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience Journal Article
| Authors: | Pak, T. K.; Dixon, B. N.; Buege, M. J.; Dao, P. H.; Leary, M. H.; Jarrett, J. C.; Duggan, T. A.; Caron, P.; Falchi, L.; Hamlin, P.; Hamilton, A.; Matasar, M. J.; Moskowitz, A.; Noy, A.; Owens, C. N.; Von Keudell, G.; Younes, A.; Zelenetz, A. D.; Kumar, A. |
| Article Title: | Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience |
| Abstract: | R +/- DHAX has been traditionally administered to inpatient due to the timing of chemotherapy administration and the perceived need for close monitoring of adverse effects. To administer R +/- DHAX outpatient, a multidisciplinary task force created clinical and educational guidelines which were implemented through two phases: pilot and expansion. The pilot program determined the feasibility of transitioning R +/- DHAX outpatient at a single infusion site. The expansion phase led to a service-wide implementation across all outpatient sites. A total of 40 patients were included, of which 23 patients completed all cycles, outpatient, 12 transitioned inpatient to outpatient administration, and 5 transitioned outpatient to inpatient administration. The success rate of outpatient R +/- DHAX administration was 90% (36 patients successfully completed outpatient administration/40 total patients). No cytarabine-related cerebellar or ophthalmic toxicity was reported. Outpatient R +/- DHAX saved 192 hospital days. R +/- DHAX could be successfully administered outpatient with minimal safety concerns and reduced hospital bed utilization. |
| Keywords: | cisplatin; chemotherapy; outpatient; satisfaction; toxicity; therapy; non-hodgkin lymphoma; quality improvement; stem-cell transplantation; patient; non-hodgkin-lymphoma; high-dose cytarabine; regimen; feasibility; salvage chemotherapy; younger; r +/- dhax |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 63 |
| Issue: | 4 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2022-01-01 |
| Start Page: | 876 |
| End Page: | 884 |
| Language: | English |
| ACCESSION: | WOS:000719760100001 |
| DOI: | 10.1080/10428194.2021.2002318 |
| PROVIDER: | wos |
| PUBMED: | 34784853 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work